Format

Send to

Choose Destination
See comment in PubMed Commons below
J Cyst Fibros. 2007 Apr;6(2):125-30. Epub 2006 Jul 7.

Therapeutic drug monitoring of once daily tobramycin in cystic fibrosis--caution with trough concentrations.

Author information

1
Adelaide Women's and Children's Hospital, Pharmacy Department, Australia. kingsley.coulthard@cywhs.sa.gov.au

Abstract

BACKGROUND:

: Once daily intravenous aminoglycoside dosing (ODD) is widely used to treat acute Pseudomonas aeruginosa exacerbations in patients with cystic fibrosis. Controversy exists as to what is the most appropriate method of therapeutic drug monitoring (TDM) of such therapy with recommendations including trough plasma concentrations of <1 mg/L or <2 mg/L, area under curve (AUC) and various nomograms. This study aimed to compare the exposures to ODD of tobramycin in adults and children with cystic fibrosis using the AUC and trough TDM approaches.

METHODS:

: Using a mono-exponential software program to calculate AUC from 2 plasma concentrations, AUCs were determined in 22 adults with pre-dose tobramycin concentrations <1 mg/L. The exposure of 5 children with reduced tobramycin clearances was simulated at the usual recommended dose of 10 mg/kg/daily but retaining a trough <1 mg/L.

RESULTS:

: A tobramycin dose of 10 mg/kg of tobramycin in these patients with normal serum creatinine and a trough concentration <1 mg/L resulted in exposures in excess of those associated with conventional 8-hourly dosing.

CONCLUSIONS:

: The TDM approach of a trough <1 mg/L, as used with conventional 8-hourly tobramycin dosing, is not relevant to ODD.

PMID:
16829216
DOI:
10.1016/j.jcf.2006.05.015
[Indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center